14.6 C
New York
Saturday, September 25, 2021

Solid Biosciences Inc (SLDB): The stock that only smart investors should pay attention to

Solid Biosciences Inc. (SLDB) stock face negativity on Monday night as it lost 15.88% of its value in the after-hours trading on Monday, March 15, 2021.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


SLDB revealed the data related to its ongoing IGNITE DMD Phase I/II clinical trial of its lead gene therapy candidate, SGT-001 and despite the encouraging trial results, the stock went down.  The data reported outcome measures (PROMs) from six patients. Patient 7 in IGNITE DMD was safely dosed. Additionally, the six patients previously dosed showed no new drug-related safety findings.

The President and Co-Founder of Solid Biosciences, Ilan Ganot said that the safe dosing of the seventh patient gives us increased confidence in our dosing strategy and the company will move forward with clinical development in the IGNITE DMD clinical trial.

Recent SLDB Activities

  • Inducement Grant to New Chief Legal Officer

On March 4, 2021, SLDB announced the Incentive to its newly appointed Chief Legal Officer, Erin Brennan which was approved by the board of directors.An option was given to Ms Brennan to purchase up to 325,000 shares of common stock at $8.52 per share as reported by Nasdaq on March 1, 2021.

  • Changes to the management team

Also on the same day, Joel Schneider, Ph.D., was promoted to Chief Operating Officer. The Company also announced the appointment of Clare Kahn, Ph.D., and Georgia Keresty, Ph.D., M.P.H., to its Board of Directors.

About the company

Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne muscular dystrophy. The company was co-founded in 2013 by Ilan and Annie and its headquarter is in Massachusetts, United States. Mr. Ganot is also President and Chief Executive Officer of Solid Biosciences and a member of the board of directors. SLDB is working with its lead gene therapy candidate, SGT-001 to address the disease at its core by correcting the underlying mutation that causes Duchenne.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.